Table 3.

University of Colorado School of Medicine guidelines for human subject research involving cannabis (marijuana) as of February 2016

For all studies:

Cannot accept funding for research from cannabis industry

For observational studies:

Can survey or evaluate subjects who are already using drug for medical or recreational  purposes (e.g. can ask subject to come in for a blood draw 1 hour after taking drug)

Should obtain federal Certificate of Confidentiality for the study

Cannot subsidize the purchase of the cannabis products

Cannot pay subjects to participate in the study

Cannot bring to campus cannabis products to test level of cannabinoids (e.g. from grower or  retailer)

Cannot advise or prescribe to start taking the drug, or manage it in any way.

Cannot dictate when the drug is to be given (e.g. specific times to enable pharmacokinetic  studies)

Cannot ask users to stop cannabis use to be eligible to participate in a study (e.g. no baseline  studies)

Cannot ask to stop using drug for a washout period

Cannot have subjects smoke or ingest drug anywhere on campus prior to being interviewed  or evaluated for research

Cannot advise or prescribe to start taking the drug

Cannot move people higher on waiting list for a certain product at the dispensary if they  agree to participate in a study

For interventional studies (including animal studies):

Must be conducted under an IND from the FDA

Can only use cannabis purchased from NIDA or a cannabis-derived product that has an FDA  record (FDA approved, or under IND)

Must apply for a DEA Researcher registration

Cannot add marijuana to clinical DEA license

Must use specifically designed and dedicated locations for storage and administration of the  drug

Must post study on ClinicalTrials.gov posting as Applicable Clinical Trial. Study results need to  be posted no later than 12 months after the final collection of the primary outcome data